Yes, acute myeloid leukemia can be cured in some patients, but not in all. Cure is most likely in younger, fitter adults whose leukemia has favorable genetic features. It is most likely in acute promyelocytic leukemia (APL), a subtype where the large majority of patients are now cured. For older adults and those with high-risk genetics, cure is harder. Modern targeted and lower-intensity treatments can still bring long remissions and good quality of life.
Whether AML can be cured depends on three things: the leukemia’s genetics, the patient’s age and fitness, and how deeply the disease responds to treatment. This guide explains each.
What Is Acute Myeloid Leukemia?
Acute myeloid leukemia (AML) is a cancer of the blood-forming cells in the bone marrow. Immature cells called blasts multiply out of control and fail to mature. They crowd out the normal cells that make red cells, platelets, and infection-fighting white blood cells. It is a hematological cancer that mainly affects adults, and it becomes more common with age, though children can develop it too.
Known risk factors include prior chemotherapy or radiation, benzene exposure, smoking, and some inherited conditions such as Down syndrome. Earlier blood disorders, particularly myelodysplastic syndromes and myeloproliferative neoplasms, can also progress to AML.
Symptoms and Diagnosis
AML usually develops over weeks. Symptoms come from the lack of normal blood cells: tiredness and breathlessness from anemia, infections and fevers from low neutrophils, and bruising, nosebleeds, or bleeding gums from low platelets. Some patients have swollen gums, bone pain, or an enlarged spleen. These overlap with other hematologic conditions, so testing is essential.
Diagnosis starts with a complete blood count and a blood film, which often show blasts. A bone marrow aspiration and biopsy confirms it. AML is generally diagnosed when blasts make up 20% or more of marrow cells, or at a lower count when certain defining genetic changes are present. The same sample goes for flow cytometry, chromosome analysis (cytogenetics), and gene mutation testing. Those results drive the answer to the cure question.
What Determines Whether AML Can Be Cured?
Hematologists group AML into risk categories based mainly on its genetics. The table gives simplified examples.
| Risk group | Example genetic features | Outlook with treatment |
|---|---|---|
| Acute promyelocytic leukemia | PML::RARA fusion, t(15;17) | Cured in the large majority with ATRA plus arsenic trioxide |
| Favorable | Core-binding factor changes such as t(8;21) or inv(16); NPM1 mutation without high-risk features | Good chance of long-term cure with chemotherapy alone |
| Intermediate | Many normal-karyotype cases; some FLT3-ITD cases | Cure possible; transplant often considered |
| Adverse | Complex karyotype, TP53 mutation, monosomy 7 | Cure harder; transplant is usually the main curative route |
Beyond genetics, age and fitness matter because curative treatment is demanding. Leukemia that arises after earlier chemotherapy, or evolves from MDS, tends to be harder to cure. Response matters too. Patients who reach remission quickly and have no measurable residual disease (MRD), meaning tiny amounts of leukemia detectable only by sensitive tests, do best.
Modern Treatment Approaches
Intensive Chemotherapy
For fit patients, treatment starts with induction. The classic regimen is “7+3”: seven days of cytarabine with three days of an anthracycline. The goal is complete remission, meaning fewer than 5% blasts in the marrow and recovery of blood counts. Consolidation follows with further chemotherapy or a transplant to clear remaining leukemia cells. Remission alone is not cure, because without consolidation AML almost always returns.
Targeted Therapy
Testing for mutations lets doctors add drugs aimed at specific drivers:
- FLT3 inhibitors such as midostaurin (with induction) and gilteritinib (for relapse). See our overview of FLT3-ITD positive acute myeloid leukemia.
- IDH1 and IDH2 inhibitors such as ivosidenib and enasidenib.
- Gemtuzumab ozogamicin, an antibody-drug conjugate targeting CD33, in selected favorable-risk disease.
- ATRA and arsenic trioxide for APL. They force the leukemic cells to mature and are the reason APL is now so curable.
Lower-Intensity Therapy
For older or less fit patients, venetoclax combined with a hypomethylating agent (azacitidine or decitabine) is now a standard option. It is given largely as an outpatient. It can produce remissions that last many months or longer. Some patients who respond well become fit enough to be considered for transplant.
Allogeneic Stem Cell Transplant
An allogeneic transplant replaces the patient’s marrow with a donor’s. The donor immune system also attacks remaining leukemia cells, the “graft-versus-leukemia” effect. It offers the best chance of cure in intermediate- and adverse-risk AML. It carries real risks, including infection and graft-versus-host disease, so patient selection is careful.
Advances and Research Directions
Several areas are actively being studied. These include immunotherapies such as CAR T-cells and bispecific antibodies, which remain experimental in AML. Researchers are also using MRD to guide how much treatment each patient needs and developing maintenance therapy to prevent relapse after remission. Joining a clinical trial is a reasonable option to discuss at any stage.
Key Takeaways
- AML is curable for a meaningful share of patients, especially APL and favorable-risk genetic subtypes.
- Genetic testing of the marrow is the single most important factor in predicting outcome and choosing treatment.
- Remission is the first step; consolidation or transplant is needed to aim for cure.
- Targeted drugs and venetoclax-based therapy have widened options for patients who cannot tolerate intensive chemotherapy.
- Our leukemia guide covers the other leukemia types.
Frequently Asked Questions
What does “cured” mean in AML?
Most relapses happen within the first two to three years after treatment. Someone who stays in continuous remission well beyond that is generally considered cured. Doctors often speak of long-term remission until enough time has passed.
Is AML curable in older adults?
It is possible, but less common. Older patients more often have adverse genetics and other health conditions that limit intensive treatment. Fit older adults may still receive intensive chemotherapy or a reduced-intensity transplant, and lower-intensity regimens can control the disease for long periods.
How long does AML treatment take?
Intensive induction usually involves a hospital stay of around four to six weeks. Consolidation cycles follow over several months. A transplant, if needed, adds its own recovery period. Lower-intensity therapy is typically given in continuing monthly cycles.
Can AML come back after remission?
Yes. Relapse is the main obstacle to cure, which is why consolidation, MRD monitoring, and sometimes transplant or maintenance therapy are used. If AML relapses, further treatment, including targeted drugs and transplant, can still achieve a second remission.
